Description
Propofol is a short-acting intravenous anesthetic. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. It is also used for status epilepticus if other medications have not worked. Its product was developed by Fresenius Kabi Deutschland GmbH. Propofol was approved for clinical use in China in 1994 and is currently included in China’s medical insurance. As of the first half of 2021, there are 7 manufacturers in the Chinese Propofol market, among which Fresenius Kabi Deutschland GmbH accounts for the largest market share.

According to CRI’s market research, the sales of Propofol in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the new crown epidemic on the overall medical diagnosis and treatment services, the sales decreased from CNY1.232 billion in 2019 to CNY1.308 billion in 2020, with a year-on-year decrease of 14.28%. The CAGR of sales of Propofol in China from 2016 to 2020 is 1.89%.

CRI expects that the sales of Propofol will have a restorative growth from 2021 to 2025 with the effective alleviation of the new crown epidemic. In addition, Propofol has a fast onset, stable induction, and rapid and complete recovery. Based on these advantages, the sales volume of Propofol will increase steadily in the future. Moreover, Propofol is also used in veterinary clinical anesthesia. With the expansion of China’s pet market and servitization and standardization of pet hygiene, Propofol will also expand in the pet medicine market, driving the growth of its sales and sales volume

Topics Covered:

  • The impact of COVID-19 on China’s Propofol market
  • Sales value of China’s Propofol 2016-2020
  • Competitive landscape of China’s Propofol market
  • Prices of Propofol in China
  • Prices of Propofol in China by regions and manufacturers
  • Analysis of factors affecting the development of China’s Propofol market
  • Prospect of China’s Propofol market from 2021 to 2025